Vantage Investment Advisors LLC maintained its stake in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 700 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Vantage Investment Advisors LLC’s holdings in Becton, Dickinson and were worth $137,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the company. Alliancebernstein L.P. raised its position in shares of Becton, Dickinson and by 0.4% during the 2nd quarter. Alliancebernstein L.P. now owns 368,110 shares of the medical instruments supplier’s stock worth $71,822,000 after purchasing an additional 1,303 shares during the period. Pittenger & Anderson Inc. raised its position in shares of Becton, Dickinson and by 2.6% during the 2nd quarter. Pittenger & Anderson Inc. now owns 42,550 shares of the medical instruments supplier’s stock worth $8,302,000 after purchasing an additional 1,083 shares during the period. Aberdeen Asset Management PLC UK raised its position in shares of Becton, Dickinson and by 4.8% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 137,092 shares of the medical instruments supplier’s stock worth $26,748,000 after purchasing an additional 6,280 shares during the period. Northwest Quadrant Wealth Management LLC raised its position in shares of Becton, Dickinson and by 0.4% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 6 shares during the period. Finally, HPM Partners LLC raised its position in shares of Becton, Dickinson and by 967.1% during the 2nd quarter. HPM Partners LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $1,661,000 after purchasing an additional 24,864 shares during the period. Institutional investors and hedge funds own 87.12% of the company’s stock.

In related news, EVP Ribo Alberto Mas sold 7,463 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $201.41, for a total value of $1,503,122.83. Following the completion of the transaction, the executive vice president now owns 29,323 shares in the company, valued at approximately $5,905,945.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock valued at $15,242,688 in the last 90 days. 1.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company (NYSE BDX) opened at 198.08 on Friday. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The firm has a market capitalization of $45.08 billion, a PE ratio of 57.36 and a beta of 1.05. The stock’s 50 day moving average price is $197.22 and its 200 day moving average price is $192.46.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the previous year, the company posted $2.35 EPS. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. Equities research analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.47%. The ex-dividend date of this dividend was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

A number of analysts have recently weighed in on BDX shares. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and currently has a consensus rating of “Buy” and an average target price of $200.93.

WARNING: “Vantage Investment Advisors LLC Continues to Hold Stake in Becton, Dickinson and Company (BDX)” was first published by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/vantage-investment-advisors-llc-continues-to-hold-stake-in-becton-dickinson-and-company-bdx/1616927.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.